

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

SAFETY DATA SHEET

FRS-40 SEMI-GLOSS BASE JET ORANGE AIC 7.29

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

Product name SDS code : FRS-40 SEMI-GLOSS BASE JET ORANGE AIC 7.29 : 40980729B

1.2 Relevant identified uses of the substance or mixture and uses advised against

| | Identified uses | |
|--|-----------------|--|
| Paint. Professional use Industrial use | | |
| Uses advised against | | |
| All other uses | | |
| Product use | | |

Product use

: Solvent borne coating for interior use.

1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

1.4 Emergency telephone number

| National advisory body/Poison Center | | | |
|--------------------------------------|--|--|--|
| : +33 (0)1 40 05 48 48 | | | |
| | | | |
| : +33 (0)5 34 01 34 01 | | | |
| +33 (0)5 61 60 23 30 | | | |
| : | | | |
| | | | |

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 STOT SE 3, H336

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

| Date of issue/Date of revision | : 2-11-2022 | Version : 1.01 | |
|--------------------------------|-------------|----------------|-----------|
| Date of previous issue | : 1-10-2022 | 1/19 | AkzoNobel |

| FRS-40 SEMI-GLOSS BASE JET ORANGE AIC 7.29 | | | | |
|---|----|---|--|--|
| SECTION 2: Hazards identification | | | | |
| Hazard pictograms | : | | | |
| Signal word | : | Warning | | |
| Hazard statements | : | Flammable liquid and vapor. May cause drowsiness or dizziness. | | |
| Precautionary statements | | | | |
| Prevention | : | Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Avoid breathing vapor. | | |
| Response | : | IF INHALED: Call a POISON CENTER or doctor if you feel unwell. | | |
| Storage | : | Store in a well-ventilated place. Keep container tightly closed. Keep cool. | | |
| Disposal | : | Dispose of contents and container in accordance with all local, regional, national and international regulations. | | |
| Hazardous ingredients | : | n-butyl acetate | | |
| Supplemental label elements | : | Contains methyl methacrylate. May produce an allergic reaction. Repeated exposure may cause skin dryness or cracking. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist. | | |
| Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles | : | Not applicable. | | |
| Special packaging requirem | en | <u>ts</u> | | |
| Containers to be fitted with child-resistant fastenings | : | Not applicable. | | |
| Tactile warning of danger | : | Not applicable. | | |
| 2.3 Other hazards | | | | |
| Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII | : | This mixture does not contain any substances that are assessed to be a PBT or a vPvB. | | |
| Other hazards which do not result in classification | : | None known. | | |

SECTION 3: Composition/information on ingredients

| Product/ingredient name | Identifiers | % | Regulation (EC) No. 1272/2008 [CLP] | Туре |
|---------------------------------|---|-----------|---|---------|
| -butyl acetate | REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1 | ≥25 - ≤50 | Flam. Liq. 3, H226 STOT SE 3, H336 EUH066 | [1] [2] |
| 2-methoxy-1-methylethyl acetate | REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 | ≤10 | Flam. Liq. 3, H226 STOT SE 3, H336 | [1] [2] |
| Reaction mass of ethylbenzene | REACH #: | <10 | Flam. Liq. 3, H226 | [1] [2] |
| Date of issue/Date of revision | : 2-11-2022 | Version | : 1.01 | |
| Date of previous issue | : 1-10-2022 | 2/19 | Akzo | Nobe |

| SECTION 3: Compositio | n/information on i | ngredients | | |
|---|--|------------|--|---------|
| and xylene | 01-2119488216-32 | | Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | |
| methyl methacrylate | REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6 | ≤0.3 | Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335 | [1] [2] |
| cyclohexanone | REACH #: 01-2119453616-35 CAS: 108-94-1 Index: 606-010-00-7 | ≤0.3 | Flam. Liq. 3, H226 Acute Tox. 4, H332 | [1] [2] |
| Hydrocarbons, C11-C14, n- alkanes, isoalkanes, cyclics, <2% aromatics | REACH #: 01-2119456620-43 EC: 926-141-6 | ≤0.3 | Asp. Tox. 1, H304 EUH066 | [1] |
| | | | See Section 16 for the full text of the H statements declared above. | |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII

[4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

[5] Substance of equivalent concern

[6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

| Eye contact | Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention. |
|--------------|---|
| Inhalation | : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours. |
| Skin contact | : Wash skin thoroughly with soap and water or use recognized skin cleanser. Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Clean shoes thoroughly before reuse. |

SECTION 4: First aid measures

| Ingestion | : Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. |
|----------------------------|---|
| Protection of first-aiders | : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. |

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains methyl methacrylate. May produce an allergic reaction.

Over-exposure signs/symptoms

| Eye contact | : No specific data. |
|--------------|---|
| Inhalation | : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness |
| Skin contact | : Adverse symptoms may include the following: irritation dryness cracking |
| Ingestion | : No specific data. |

4.3 Indication of any immediate medical attention and special treatment needed

| Notes to physician | : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours. |
|---------------------|--|
| Specific treatments | : No specific treatment. |



SECTION 5: Firefighting measures

| 5.1 Extinguishing media | |
|---|---|
| Suitable extinguishing media | : Use dry chemical, CO ₂ , water spray (fog) or foam. |
| Unsuitable extinguishing media | : Do not use water jet. |
| 5.2 Special hazards arising | rom the substance or mixture |
| Hazards from the substance or mixture | : Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. |
| Hazardous combustion products | : Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides halogenated compounds metal oxide/oxides |
| 5.3 Advice for firefighters | |
| Special protective actions for fire-fighters | : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool. |
| Special protective equipment for fire-fighters | : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents. |
| | |

SECTION 6: Accidental release measures

| 6.1 Personal precautions, pro | tective equipment and emergency procedures |
|--------------------------------|---|
| For non-emergency personnel | : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment. |
| For emergency responders | : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". |
| 6.2 Environmental precautions | : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). |
| 6.3 Methods and materials fo | r containment and cleaning up |
| Small spill | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an |

contractor.

appropriate waste disposal container. Dispose of via a licensed waste disposal



SECTION 6: Accidental release measures

| Large spill | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product. |
|---------------------------------|--|
| 6.4 Reference to other sections | : See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information. |

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

| Protective measures | : Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container. |
|--|---|
| Advice on general occupational hygiene | : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures. |

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Seveso Directive - Reporting thresholds

Danger criteria

| | Notification and MAPP threshold | Safety report threshold |
|-----|---------------------------------|-------------------------|
| P5c | 5000 tonne | 50000 tonne |

7.3 Specific end use(s)

| Recommendations | : Not available. |
|--------------------------------------|------------------|
| Industrial sector specific solutions | : Not available. |



SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

| Product/ingredient name | Exposure limit values |
|--|---|
| ┏-butyl acetate | Ministry of Labor (France, 3/2020). Notes: Indicative limit |
| | values (circular) STEL: 940 mg/m ³ 15 minutes. Form: Risk for sensitisation STEL: 200 ppm 15 minutes. Form: Risk for sensitisation |
| | TWA: 710 mg/m ³ 8 hours. Form: Risk for sensitisation TWA: 150 ppm 8 hours. Form: Risk for sensitisation |
| 2-methoxy-1-methylethyl acetate | Ministry of Labor (France, 10/2016). Absorbed through skin. Notes: Labour Act , Art 4412-149 (Regulatory binding |
| | exposure limits) |
| | STEL: 550 mg/m ³ 15 minutes. |
| | STEL: 100 ppm 15 minutes. |
| | TWA: 275 mg/m ³ 8 hours. |
| | TWA: 50 ppm 8 hours. |
| Reaction mass of ethylbenzene and xylene | Ministry of Labor (France, 3/2020). Absorbed through skin. |
| | Notes: Binding regulatory limit values (article R. 4412-149 of |
| | the Labor Code) |
| | STEL: 442 mg/m ³ 15 minutes. Form: Risk for sensitisation |
| | STEL: 100 ppm 15 minutes. Form: Risk for sensitisation TWA: 221 mg/m ³ 8 hours. Form: Risk for sensitisation |
| | TWA: 22 mig/m o hours. Form: Risk for sensitisation |
| methyl methacrylate | Ministry of Labor (France, 3/2020). Notes: Binding regulatory |
| methymethaciylate | limit values (article R. 4412-149 of the Labor Code) |
| | STEL: 410 mg/m ³ 15 minutes. Form: Risk for sensitisation |
| | STEL: 100 ppm 15 minutes. Form: Risk for sensitisation |
| | TWA: 205 mg/m ³ 8 hours. Form: Risk for sensitisation |
| | TWA: 50 ppm 8 hours. Form: Risk for sensitisation |
| cyclohexanone | Ministry of Labor (France, 3/2020). Notes: Binding regulatory |
| • | limit values (article R. 4412-149 of the Labor Code) |
| | STEL: 81.6 mg/m ³ 15 minutes. Form: Risk for sensitisation |
| | STEL: 20 ppm 15 minutes. Form: Risk for sensitisation |
| | TWA: 40.8 mg/m ³ 8 hours. Form: Risk for sensitisation |
| | TWA: 10 ppm 8 hours. Form: Risk for sensitisation |
| • | contains ingredients with exposure limits, personal, workplace |
| | biological monitoring may be required to determine the effectiveness on or other control measures and/or the necessity to use respiratory |
| | pment. Reference should be made to monitoring standards, such as |
| | European Standard EN 689 (Workplace atmospheres - Guidance for |
| | t of exposure by inhalation to chemical agents for comparison with |
| | d measurement strategy) European Standard EN 14042 (Workplace |
| | Guide for the application and use of procedures for the assessment |
| | chemical and biological agents) European Standard EN 482 |
| | nospheres - General requirements for the performance of procedures |
| tor the measure | ement of chemical agents) Reference to national guidance |
| | methods for the determination of hazardous substances will also be |

SECTION 8: Exposure controls/personal protection Product/ingredient name Value Population Effects Туре Exposure p-butyl acetate DNEL 3.4 mg/kg Systemic Long term Oral General population bw/day DNEL 3.4 mg/kg General Systemic Long term Dermal population bw/day DNEL Long term Dermal 7 mg/kg Workers Systemic bw/day DNEL Long term 12 mg/m³ General Systemic Inhalation population DNEL Long term 48 mg/m³ Workers Systemic Inhalation DNEL Long term 102.34 mg/ Local General Inhalation population m³ DNEL Long term 480 mg/m³ Workers Local Inhalation DNEL Short term 859.7 mg/ General Local Inhalation population m³ DNEL Short term 859.7 mg/ General Systemic Inhalation population m³ DNEL Short term 960 mg/m³ Workers Local Inhalation DNEL Workers Systemic Short term 960 mg/m³ Inhalation DNEL Reaction mass of ethylbenzene and Long term Oral 1.6 mg/kg General Systemic xylene bw/day population DNEL Long term 14.8 mg/m General Systemic Inhalation population DNEL Long term 77 mg/m³ Workers Systemic Inhalation DNEL Long term Dermal 108 mg/kg General Systemic bw/day population DNEL Long term Dermal 180 mg/kg Workers Systemic bw/day DNEL 289 mg/m³ Short term Workers Local Inhalation DNEL 289 mg/m³ Short term Workers Systemic Inhalation methyl methacrylate DNEL Long term Dermal 8.2 mg/kg General Systemic bw/day population DNEL Long term Dermal 13.67 mg/ Workers Systemic kg bw/day DNEL Long term 74.3 mg/m³ General Systemic Inhalation population DNEL Long term General 104 mg/m³ Local Inhalation population DNEL Long term 208 mg/m³ Workers Local Inhalation DNEL Long term 208 mg/m³ Workers Systemic Inhalation cyclohexanone DNEL Short term Dermal 1 mg/kg General Systemic bw/day population DNEL 1 mg/kg General Systemic Long term Dermal population bw/day DNEL Short term Oral 1.5 mg/kg General Systemic population bw/day DNEL General Long term Oral 1.5 mg/kg Systemic bw/day population DNEL Short term Dermal 4 mg/kg Workers Systemic bw/day DNEL Long term Dermal 4 mg/kg Workers Systemic bw/day Date of issue/Date of revision : 2-11-2022 Version :101

8/19



| DNEL | Long term | 10 mg/m ³ | General | Systemic |
|------|------------|----------------------|------------|----------|
| | Inhalation | | population | |
| DNEL | Long term | 20 mg/m ³ | General | Local |
| | Inhalation | | population | |
| DNEL | Short term | 20 mg/m ³ | General | Systemic |
| | Inhalation | | population | |
| DNEL | Short term | 40 mg/m ³ | General | Local |
| | Inhalation | | population | |
| DNEL | Long term | 40 mg/m ³ | Workers | Local |
| | Inhalation | | | |
| DNEL | Long term | 40 mg/m ³ | Workers | Systemic |
| | Inhalation | | | |
| DNEL | Short term | 80 mg/m³ | Workers | Local |
| | Inhalation | | | |
| DNEL | Short term | 80 mg/m³ | Workers | Systemic |
| | Inhalation | | | |

PNECs

No PNECs available.

Date of previous issue

:1-10-2022

| 8.2 Exposure controls | | | |
|----------------------------------|---|--|---|
| Appropriate engineering controls | ventilation or other er contaminants below a controls also need to | te ventilation. Use process enclosures igineering controls to keep worker exp any recommended or statutory limits. keep gas, vapor or dust concentration explosion-proof ventilation equipment | osure to airborne The engineering s below any lower |
| Individual protection meas | ures | | |
| Hygiene measures | before eating, smokir Appropriate technique Wash contaminated e | ns and face thoroughly after handling c ng and using the lavatory and at the en es should be used to remove potentiall clothing before reusing. Ensure that ey ose to the workstation location. | d of the working period. ly contaminated clothing. |
| Eye/face protection | assessment indicates gases or dusts. If co | lying with an approved standard shoul this is necessary to avoid exposure to ntact is possible, the following protection nt indicates a higher degree of protection | o liquid splashes, mists, on should be worn, |
| Skin protection | | | |
| Hand protection | be worn at all times w this is necessary. Co check during use that should be noted that different for different | npervious gloves complying with an ap when handling chemical products if a ris insidering the parameters specified by t the gloves are still retaining their protect the time to breakthrough for any glove glove manufacturers. In the case of m he protection time of the gloves canno | sk assessment indicates the glove manufacturer, ective properties. It material may be hixtures, consisting of |
| | protection class of 6 (recommended. Reco When only brief conta (breakthrough time > Recommended glove | equently repeated contact may occur, breakthrough time >480 minutes acco ommended gloves: Viton ® or Nitrile, th act is expected, a glove with protection 30 minutes according to EN374) is rec s: Nitrile, thickness ≥ 0.12 mm. laced regularly and if there is any sign | ording to EN374) is nickness ≥ 0.38 mm. n class of 2 or higher commended. |
| | The performance or e chemical damage and | effectiveness of the glove may be redu d poor maintenance. | ced by physical/ |
| Date of issue/Date of revision | : 2-11-2022 | Version : 1.01 | |
| Date of previous issue | : 1-10-2022 | 9/19 | AkzoNobel |

SECTION 8: Exposure controls/personal protection

| | The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment. |
|---------------------------------|--|
| Body protection | : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods. |
| Other skin protection | Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. |
| Respiratory protection | : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use. |
| Environmental exposure controls | : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels. |

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Annooronoo

| <u>Appearance</u> | | |
|---|---|---|
| Physical state | : | Liquid. |
| Color | : | Orange. |
| Odor | : | Characteristic. |
| Odor threshold | : | Not available. |
| рН | : | Not available. |
| Melting point/freezing point | : | Not available. |
| Initial boiling point and boiling range | : | Not available. |
| Flash point | : | Closed cup: 28°C |
| Evaporation rate | : | Not available. |
| Flammability (solid, gas) | : | Not available. |
| Upper/lower flammability or explosive limits | : | Not available. |
| Vapor pressure | : | Not available. |
| Vapor density | : | Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Weighted average: 4.05 (Air = 1) |
| Density | : | 1.267 g/cm ³ |
| Solubility(ies) | : | Insoluble in the following materials: cold water. |
| Partition coefficient: n-octanol/ water | : | Not available. |
| Auto-ignition temperature | : | Not available. |
| Decomposition temperature | : | Not available. |
| Viscosity | : | Kinematic (room temperature): 7.89 cm²/s Kinematic (40°C): 1.01 cm²/s |



SECTION 10: Stability and reactivity

| 10.1 Poactivity | : No specific test data related to reactivity available for this product or its ingredients. |
|--|--|
| 10.1 Reactivity | |
| 10.2 Chemical stability | : The product is stable. |
| | |
| 10.3 Possibility of hazardous reactions | : Under normal conditions of storage and use, hazardous reactions will not occur. |
| | |
| 10.4 Conditions to avoid | : Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, |
| | braze, solder, drill, grind or expose containers to heat or sources of ignition. |
| | |
| 10.5 Incompatible materials | Reactive or incompatible with the following materials: oxidizing materials |
| | |
| 10.6 Hazardous | : Under normal conditions of storage and use, hazardous decomposition products |
| decomposition products | should not be produced. |

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

| prbutyl acetate LC50 Inhalation Gas. LC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation Vapor LD50 Dermal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LC50 Inhalation Gas. ethylbenzene and xylene methyl methacrylate LC50 Inhalation Vapor tLC50 Inhalation Vapor LC50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 | Product/ingredient name | Result | Species | Dose | Exposure |
|--|-------------------------|-----------------------|------------|-------------------------|----------|
| LC50 Inhalation Vapor Mouse 6 g/m³ 2 hours LD50 Dermal Rabbit >17600 mg/kg - LD50 Oral Guinea pig 4700 mg/kg - LD50 Oral Mouse 6 g/kg - LD50 Oral Mouse 6 g/kg - LD50 Oral Rabbit 3200 mg/kg - LD50 Oral Rabbit 3200 mg/kg - LD50 Oral Rat 10768 mg/kg - LD50 Oral Rat 10768 mg/kg - LD50 Oral Rat 5000 ppm 4 hours Ethylbenzene and xylene LC50 Inhalation Vapor Mouse 18500 mg/m³ 2 hours LD50 Dermal Ratbit >5 g/kg - - LD50 Intraperitoneal Guinea pig 1890 mg/kg - LD50 Intraperitoneal Mouse 3625 mg/kg - LD50 Varal Guinea pig 5954 mg/kg - LD50 Subcutaneous Guinea pig 5954 mg/kg - LD50 Intraperitoneal Rat 7088 mg/kg - LD50 Subcutaneous Rat 7088 mg/kg - LD50 Subcutaneous Rat 7088 mg/kg - LD50 Intraperitoneal Guinea pig | p-butyl acetate | LC50 Inhalation Gas. | Rat | 390 ppm | 4 hours |
| LD50 Dermal LD50 IntraperitonealRabbit>17600 mg/kg-LD50 Intraperitoneal LD50 OralMouse1230 mg/kg-LD50 Oral LD50 OralMouse6 g/kg-LD50 Oral LD50 OralRabbit3200 mg/kg-LD50 Oral LD50 OralRat10768 mg/kg-LD50 Oral LD50 OralRat10768 mg/kg-LC50 Inhalation Gas.Rat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 IntraperitonealMouse18500 mg/m³2 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig1900 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse945 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 SubcutaneousMouse3625 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7872 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1230 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg- </td <td>, ,</td> <td>LC50 Inhalation Vapor</td> <td>Mouse</td> <td></td> <td>2 hours</td> | , , | LC50 Inhalation Vapor | Mouse | | 2 hours |
| LD50 Intraperitoneal LD50 OralMouse Guinea pig Guinea pig 4700 mg/kg-Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat10768 mg/kg-LC50 Inhalation Gas.Rat10768 mg/kgLC50 Inhalation Gas.Rat78000 mg/m³2 hoursLC50 Inhalation Vapor LC50 Inhalation VaporRat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 DermalGuinea pig Guinea pig1890 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig945 mg/kg-LD50 Oral LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralGuinea pig Guinea pig5954 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Subcutaneous LD50 SubcutaneousGuinea pig Guinea pig5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7808 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 IntraperitonealGuinea pig Guinea pig930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg </td <td></td> <td>LD50 Dermal</td> <td>Rabbit</td> <td></td> <td>-</td> | | LD50 Dermal | Rabbit | | - |
| LD50 OralGuinea pig Mouse4700 mg/kg G /kg-LD50 OralLD50 OralRabbit3200 mg/kg-LD50 OralRat10768 mg/kg-LD50 OralRat10768 mg/kg-LD50 OralRat5000 ppm4 hoursethylbenzene and xyleneLC50 Inhalation VaporMouse18500 mg/m³2 hoursLC50 Inhalation VaporRat78000 mg/m³4 hoursLC50 Inhalation VaporRat78000 mg/m³4 hoursLD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRatit1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitone | | LD50 Intraperitoneal | Mouse | | - |
| LD50 Oral LD50 OralMouse6 g/kg-Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat10768 mg/kg-LC50 Inhalation Vapor LD50 DermalMouse18500 mg/m³2 hoursLC50 Inhalation Vapor LD50 DermalRat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 IntraperitonealRat>5 g/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig1890 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 SubcutaneousMouse5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat </td <td></td> <td></td> <td>Guinea pig</td> <td>4700 mg/kg</td> <td>-</td> | | | Guinea pig | 4700 mg/kg | - |
| LD50 Oral LD50 Oral LD50 Oral ethylbenzene and xylene methyl methacrylateLD50 Oral LC50 Inhalation Gas.Rat10768 mg/kg 5000 ppm-LC50 Inhalation Vapor LC50 Inhalation VaporMouse18500 mg/m³2 hoursLC50 Inhalation Vapor LD50 DermalRat78000 mg/m³4 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig5954 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 SubcutaneousRat7872 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig S954 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intrap | | LD50 Oral | | | - |
| Reaction mass of ethylbenzene and xylene methyl methacrylateLD50 Oral LC50 Inhalation Gas.Rat10768 mg/kg s000 ppm4 hoursLC50 Inhalation Gas.Rat5000 ppm4 hoursLC50 Inhalation Vapor LD50 IntraperitonealMouse18500 mg/m³2 hoursLD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealRat7088 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1 | | LD50 Oral | Rabbit | | - |
| Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat5000 ppm4 hoursLC50 Inhalation Vapor LD50 Intraperitoneal LD50 IntraperitonealMouse18500 mg/m³2 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Rat1890 mg/kg-LD50 Intraperitoneal | | LD50 Oral | Rat | 10768 mg/kg | - |
| methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LD50 DermalMouse18500 mg/m³2 hoursLD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7870 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealRabbit1 mL/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperi | | LC50 Inhalation Gas. | Rat | | 4 hours |
| LC50Inhalation VaporRat78000 mg/m³4 hoursLD50DermalRabbit>5 g/kg-LD50IntraperitonealGuinea pig1890 mg/kg-LD50IntraperitonealMouse945 mg/kg-LD50IntraperitonealRat1328 mg/kg-LD50OralGuinea pig5954 mg/kg-LD50OralGuinea pig5954 mg/kg-LD50OralMouse3625 mg/kg-LD50OralRat7872 mg/kg-LD50OralRat7872 mg/kg-LD50SubcutaneousMouse5954 mg/kg-LD50SubcutaneousMouse5954 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50IntraperitonealGuinea pig930 mg/kg-LD50IntraperitonealGuinea pig930 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealRabbit1540 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1300 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1 | | LC50 Inhalation Vapor | Mouse | 18500 ma/m ³ | 2 hours |
| LD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 DermalRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-< | , , | | Rat | | 4 hours |
| LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg- | | | | | - |
| LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 DermalRat7088 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1130 mg/kg-LD50 Oral< | | | Guinea pig | | - |
| LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | | - |
| LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat100 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | | - |
| LD50 Oral Mouse 3625 mg/kg - LD50 Oral Rabbit 8700 mg/kg - LD50 Oral Rat 7872 mg/kg - LD50 Subcutaneous Guinea pig 5954 mg/kg - LD50 Subcutaneous Mouse 5954 mg/kg - LD50 Subcutaneous Rat 7088 mg/kg - LD50 Subcutaneous Rat 8000 ppm 4 hours LD50 Dermal Rabbit 1 mL/kg - LD50 Dermal Guinea pig 930 mg/kg - LD50 Intraperitoneal Guinea pig 930 mg/kg - LD50 Intraperitoneal Mouse 1230 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rat 1130 mg/kg - | | | Guinea pig | | - |
| LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | | - |
| LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | | - |
| LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | | - |
| LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | | - |
| LD50 SubcutaneousRat7088 mg/kg-LC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1240 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | | - |
| cyclohexanoneLC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | Rat | | - |
| LD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1400 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | cyclohexanone | LC50 Inhalation Gas. | Rat | | 4 hours |
| LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | LD50 Dermal | Rabbit | | - |
| LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | LD50 Intraperitoneal | Guinea pig | | - |
| LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | | - |
| LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | Mouse | | - |
| LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | Rabbit | | - |
| LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | Rabbit | | - |
| LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | Rat | | - |
| LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg- | | | | 1130 mg/kg | - |
| LD50 Oral Rat 1800 mg/kg - LD50 Oral Rat 1620 uL/kg - | | | Mouse | | - |
| LD50 Oral Rat 1620 uL/kg - | | | Rat | | - |
| | | | | | - |
| | | | | | - |
| e of issue/Date of revision : 2-11-2022 Version : 1.01 | | | • | · | • |

11/19



SECTION 11: Toxicological information

Conclusion/Summary : Not available.

| Product/ingredient name | Result | Species | Score | Exposure | Observation |
|---|--------------------------|---------|-------|---------------|-------------|
| p -butyl acetate | Eyes - Moderate irritant | Rabbit | - | 100 mg | - |
| - | Skin - Moderate irritant | Rabbit | - | 24 hours 500 | - |
| | | | | mg | |
| Reaction mass of ethylbenzene and xylene | Eyes - Mild irritant | Rabbit | - | 87 mg | - |
| | Eyes - Severe irritant | Rabbit | - | 24 hours 5 | - |
| | | | | mg | |
| | Skin - Mild irritant | Rat | - | 8 hours 60 UI | - |
| | Skin - Moderate irritant | Rabbit | - | 24 hours 500 | - |
| | | | | mg | |
| | Skin - Moderate irritant | Rabbit | - | 100 % | - |
| cyclohexanone | Eyes - Severe irritant | Rabbit | - | 24 hours 250 | - |
| | | | | ug | |
| | Eyes - Severe irritant | Rabbit | - | 20 mg | - |
| | Skin - Mild irritant | Rabbit | - | 500 mg | - |
| Conclusion/Summary | : Not available. | · | 1 | • | |
| Sensitization | | | | | |

| Sensitization | | |
|---------------------------|---|----------------|
| Conclusion/Summary | : | Not available. |
| <u>Mutagenicity</u> | | |
| Conclusion/Summary | : | Not available. |
| Carcinogenicity | | |
| Conclusion/Summary | : | Not available. |
| Reproductive toxicity | | |
| Conclusion/Summary | : | Not available. |
| <u>Teratogenicity</u> | | |
| Conclusion/Summary | : | Not available. |

Specific target organ toxicity (single exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|---|--|-------------------|--|
| p-butyl acetate 2-methoxy-1-methylethyl acetate Reaction mass of ethylbenzene and xylene methyl methacrylate | Category 3 Category 3 Category 3 Category 3 | - | Narcotic effects Narcotic effects Respiratory tract irritation Respiratory tract |
| | Category 5 | _ | irritation |

Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|--|------------|-------------------|---------------|
| Reaction mass of ethylbenzene and xylene | Category 2 | - | - |

Aspiration hazard

| Product/ingredient name | Result | |
|---|--|--|
| Reaction mass of ethylbenzene and xylene Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics | ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 | |

Information on the likely : Not available. routes of exposure



SECTION 11: Toxicological information

| Potential acute health effect | | |
|-------------------------------|--|----|
| Eye contact | : No known significant effects or critical hazards. | |
| Inhalation | : Can cause central nervous system (CNS) depression. May cause drowsiness dizziness. | or |
| Skin contact | : Defatting to the skin. May cause skin dryness and irritation. | |
| Ingestion | : Can cause central nervous system (CNS) depression. | |

Symptoms related to the physical, chemical and toxicological characteristics

| Eye contact | : No specific data. |
|--------------|---|
| Inhalation | : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness |
| Skin contact | : Adverse symptoms may include the following: irritation dryness cracking |
| Ingestion | : No specific data. |

Delayed and immediate effects and also chronic effects from short and long term exposure

| Short term exposure | |
|--------------------------------|--|
| Potential immediate effects | : Not available. |
| Potential delayed effects | : Not available. |
| Long term exposure | |
| Potential immediate effects | : Not available. |
| Potential delayed effects | : Not available. |
| Potential chronic health eff | ects |
| Not available. | |
| Conclusion/Summary | : Not available. |
| General | : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. |
| Carcinogenicity | : No known significant effects or critical hazards. |
| Mutagenicity | : No known significant effects or critical hazards. |
| Reproductive toxicity | : No known significant effects or critical hazards. |
| | |

Other information

: Not available.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment, but contains substance(s) hazardous to the environment. See section 3 for details.

| Date of issue/Date of revision | : 2-11-2022 | Version : 1.01 | |
|--------------------------------|-------------|----------------|-----------|
| Date of previous issue | : 1-10-2022 | 13/19 | AkzoNobel |

SECTION 12: Ecological information

| Product/ingredient name | Result | Species | Exposure |
|---|-------------------------------------|--|----------|
| | | • | - |
| n-butyl acetate | Acute LC50 32 mg/l Marine water | Crustaceans - Artemia salina | 48 hours |
| | Acute LC50 100000 µg/l Fresh water | Fish - Lepomis macrochirus | 96 hours |
| | Acute LC50 18000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 185000 µg/l Marine water | Fish - Menidia beryllina | 96 hours |
| | Acute LC50 62000 µg/l Fresh water | Fish - Danio rerio | 96 hours |
| Reaction mass of ethylbenzene and xylene | Acute LC50 13400 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| methyl methacrylate | Acute LC50 191000 µg/l Fresh water | Fish - Lepomis macrochirus - Juvenile (Fledgling, Hatchling, Weanling) | 96 hours |
| | Acute LC50 159100 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 160200 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 150000 µg/l Fresh water | Fish - Pimephales promelas - Adult | 96 hours |
| | Acute LC50 130000 µg/l Fresh water | Fish - Pimephales promelas - Adult | 96 hours |
| cyclohexanone | Acute EC50 32.9 mg/l Fresh water | Algae - Chlamydomonas reinhardtii - Exponential growth phase | 72 hours |
| | Acute LC50 630000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 527000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 732000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |

Conclusion/Summary

: Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

| Product/ingredient name | LogPow | BCF | Potential |
|--|--------------|-------------|------------|
| p -butyl acetate | 2.3 | - | low |
| 2-methoxy-1-methylethyl acetate | 1.2 | - | low |
| Reaction mass of ethylbenzene and xylene | 3.12 | 8.1 to 25.9 | low |
| methyl methacrylate cyclohexanone | 1.38 0.86 | - | low low |

12.4 Mobility in soil

| Soil/water partition coefficient (Koc) | : Not available. |
|--|------------------|
| Mobility | : Not available. |

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.



SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

| <u>Product</u> | |
|-------------------------|--|
| Methods of disposal | : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. |
| Hazardous waste | : The classification of the product may meet the criteria for a hazardous waste. |
| Disposal considerations | Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority. |

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

| Waste code | Waste designation | | | |
|-------------------------|--|--|--|--|
| EWC 08 01 11* | waste paint and varnish containing organic solvents or other hazardous substances | | | |
| Packaging | | | | |
| Methods of disposal | : The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. | | | |
| Disposal considerations | Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions. | | | |
| Special precautions | : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. | | | |

SECTION 14: Transport information

| | ADR/RID | IMDG | | ΙΑΤΑ |
|------------------------------------|--------------------|--------|----------|-----------|
| 14.1 UN number | UN1263 | UN1263 | UN1263 | |
| 14.2 UN proper shipping name | PAINT | PAINT | PAINT | |
| 14.3 Transport hazard class(es) | 3 | 3 | 3 | |
| 14.4 Packing group | | | | |
| Date of issue/Date of rev | rision : 2-11-2022 | Versic | on :1.01 | |
| Date of previous issue | : 1-10-2022 | 15/19 | | AkzoNobel |

| SECTION 14: Transport information | | | | | | |
|--|--|---|---|--|------------------------------------|--|
| 14.5 Environmental hazards | No. | | | No. | No. | |
| Additional informat | <u>ion</u> | | | | | |
| ADR/RID | | : | | ception This class 3 viscous liqu 50 L according to 2.2.3.1.5.1. | id is not subject to regulation in | |
| IMDG | | : | Emergency schedules F-E, _S-E_ Viscous liquid exception This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.3.2.5. | | | |
| 14.6 Special precaut user | 14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do it the event of an accident or spillage. | | | | | |
| 14.7 Transport in bulk : Not applicable. according to IMO instruments | | | | | | |
| SECTION 15: Regulatory information | | | | | | |
| 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>EU Regulation (EC) No. 1907/2006 (REACH)</u> <u>Annex XIV - List of substances subject to authorization</u> | | | | | | |

| Annex XIV | - | |
|---|--------------------------|---|
| None of the components a | re listed. | |
| Substances of very high | <u>concern</u> | |
| None of the components a | re listed. | |
| Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles | : Not applicable. | |
| Other EU regulations | | |
| VOC | | ctive 2004/42/EC on VOC apply to this product. Refer to the chnical data sheet for further information. |
| VOC for Ready-for-Use Mixture | : Not applicable. | |
| Industrial emissions (integrated pollution prevention and control) - Air | : Not listed | |
| Industrial emissions (integrated pollution prevention and control) - Water | : Not listed | |
| Ozone depleting substanc | <u>es (1005/2009/EU)</u> | |
| Not listed. | | |
| Prior Informed Consent (P | <u>IC) (649/2012/EU)</u> | |
| Not listed. | | |
| Seveso Directive | | |
| ate of issue/Date of revision | : 2-11-2022 | Version : 1.01 |

| Date of issue/Date of revision | : 2-11-2022 | Version : 1.01 | |
|--------------------------------|-------------|----------------|-----------|
| Date of previous issue | : 1-10-2022 | 16/19 | AkzoNobel |

SECTION 15: Regulatory information

This product is controlled under the Seveso Directive.

Danger criteria

Category

| P5c | |
|-----|--|

| P50 | | |
|---|--|---|
| National regulations | | |
| Industrial use | The information contained in this safety data sho own assessment of workplace risks, as required legislation. The provisions of the national health to the use of this product at work. | by other health and safety |
| Social Security Code, Articles L 461-1 to L 46 | in-butyl acetate in-acetation mass of ethylbenzene and xylene methyl methacrylate cyclohexanone | RG 84 RG 4bis, RG 84 RG 82 RG 84 |
| Reinforced medical surveillance | : Decree n ° 2012-135 of January 30, 2012 relatir occupational medicine: not applicable | ng to the organization of |
| International regulations | <u>§</u> | |
| Chemical Weapon Conv | rention List Schedules I, II & III Chemicals | |
| Not listed. | | |
| Montreal Protocol Not listed. | | |
| Stockholm Convention of Not listed. | on Persistent Organic Pollutants | |
| Rotterdam Convention of Not listed. | on Prior Informed Consent (PIC) | |
| UNECE Aarhus Protoco Not listed. | l on POPs and Heavy Metals | |
| Inventory list Europe | : Not determined. | |
| 5.2 Chemical Safety Assessment | : No Chemical Safety Assessment has been carri | ied out. |
| SECTION 16: Othe | er information | |
| Indicates information the second s | hat has changed from previously issued version. | |
| Abbreviations and acronyms | ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging F 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statemen N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number | |

SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Date of issue/Date of revision | : 2-11-2022 | Version : 1.01 | |
|--------------------------------|-------------|----------------|-----------|
| Date of previous issue | : 1-10-2022 | 17/19 | AkzoNobel |

| FRS-40 SEMI-GLOSS BASE JET ORANGE AIC 7.29 | | | | |
|---|------------------|--|---|--|
| SECTION 16: Other information | | | | |
| Classification Justification | | | | |
| Flam. Liq. 3, H226 STOT SE 3, H336 | | | On basis of test data Calculation method | |
| Full text of abbreviated H | statements | | | |
| <mark>⊮</mark> 225 | | Highly flammable lig | uid and vapor. | |
| H226 | | Flammable liquid an | nd vapor. | |
| H304 | | May be fatal if swall | owed and enters airways. | |
| H312 | | Harmful in contact w | vith skin. | |
| H315 | | Causes skin irritatio | n. | |
| H317 | | May cause an allerg | jic skin reaction. | |
| H319 | | Causes serious eye | | |
| H332 | | Harmful if inhaled. | | |
| H335 | | May cause respirato | bry irritation. | |
| H336 | | May cause drowsine | | |
| H373 | | May cause damage to organs through prolonged or repeated | | |
| exposure. | | | | |
| H412 Harmful to aquatic | | ife with long lasting effects. | | |
| EUH066 Repeated exposure may cause skin dryness or cracking | | | | |
| Full text of classifications | [CLP/GHS] | | | |
| Acute Tox. 4 | | ACUTE TOXICITY - | - Category 4 | |
| Aquatic Chronic 3 | | | (LONG-TERM) - Category 3 | |
| Asp. Tox. 1 | | ASPIRATION HAZA | | |
| Eye Irrit. 2 | | | MAGE/ EYE IRRITATION - Category 2 | |
| Flam. Liq. 2 | | FLAMMABLE LIQUI | | |
| Flam. Liq. 3 | | FLAMMABLE LIQU | | |
| Skin Irrit. 2 | | | /IRRITATION - Category 2 | |
| Skin Sens. 1 | | SKIN SENSITIZATI | | |
| STOT RE 2 | | | ORGAN TOXICITY (REPEATED | |
| | | EXPOSURE) - Cate | | |
| STOT SE 3 | | | ORGAN TOXICITY (SINGLE EXPOSURE) - | |
| | | Category 3 | | |
| Date of printing | : 2 November 2 | 022 | | |
| Date of issue/ Date of | : 2 November 2 | 022 | | |
| revision | . 211010110012 | | | |
| Date of previous issue | : 1 October 2022 | | | |
| Version | : 1.01 | | | |

Version Unique ID

Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

| Date of issue/Date of revision | : 2-11-2022 | Version : 1.01 | |
|--------------------------------|-------------|----------------|-----------|
| Date of previous issue | : 1-10-2022 | 18/19 | AkzoNobel |

SECTION 16: Other information

